Prix Broncus Holding Corp (02216.HK)

Broncus Holding Corp. engages in the research and development, and manufacturing, and commercialization of medical devices and consumables. The company is headquartered in Hangzhou, Zhejiang and currently employs 193 full-time employees. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.